Classifications

• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/32—One oxygen, sulfur or nitrogen atom
  • C07D239/34—One oxygen atom
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P9/00—Drugs for disorders of the cardiovascular system
  • A61P9/12—Antihypertensives
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
  • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
  • C07D209/04—Indoles; Hydrogenated indoles
  • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
  • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
  • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
  • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
  • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
  • C07D235/14—Radicals substituted by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
  • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
  • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
  • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
  • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
  • C07D239/48—Two nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
  • C07D333/02—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
  • C07D333/04—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
  • C07D333/06—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
  • C07D333/14—Radicals substituted by singly bound hetero atoms other than halogen
  • C07D333/20—Radicals substituted by singly bound hetero atoms other than halogen by nitrogen atoms
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
  • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
  • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
  • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
  • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
  • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
  • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
• • C—CHEMISTRY; METALLURGY
  • C07—ORGANIC CHEMISTRY
  • C07D—HETEROCYCLIC COMPOUNDS
  • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
  • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
  • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Definitions

• the present invention is concerned with heterocyclic carbon compounds of the pyrimidine series (Class 260/239.75), and with drug bio-affecting and body-treating processes employing these compounds (Class 424/251).
• Compounds of the instant invention (1) are comprised of a propoxy-pyrimidine ring structural component, (2) the pyrimidine ring is optimally substituted in the 2- position with a hydrazino or hydrazono moiety, and (3) Z can be alkylthienyl, alkylbenzothienyl, alkylbenzofuranyl, or alkylbenzimidazolyl in addition to alkylindolyl, alkylphenyl, and alkyl.
• This invention concerns a series of cardiovascular agents having vasodilating and beta-adrenergic blocking activities which make them useful as antihypertensive agents.
• the invention comprises compounds of general formula I and the pharmaceutically acceptable acid addition salts thereof. ##STR2##
• R 1 can be C 1-6 alkyl, amino, acylamino, cyano, halogen, or hydrogen
• R 2 can be amino, alkylcarbonylamino, halogen, hydrazino, hydrazono, hydrogen, or phenyl
• alk is C 1-6 alkylene, either straight chain or branched
• Z is selected from the group consisting of hydrogen, phenyl, indole, thienyl, benzothienyl, benzofuranyl, and benzimidazolyl.
• R 2 is only hydrazino or hydrazono while in the second group (IB) R 2 is hydrogen, amino, C 1-4 alkylcarbonylamino, cyano, or halogen and Z is only indole, thiophene, benzothiophene, benzofuran, and benzimidazole.
• R 1 can be alkyl containing from 1 to 6 carbon atoms, either straight chain or branched, amino, C 1-4 alkylcarbonylamino, cyano, halogen or hydrogen.
• R 1 is hydrogen, C 1-4 alkyl, and halogen, especially bromo.
• R 2 can be amino, C 1-4 alkylcarbonylamino, halogen, hydrazino, hydrazono, hydrogen, or phenyl, with hydrazino and hydrazono groups being preferred.
• alk is an alkylene group containing 1-6 carbon atoms, either straight chain or branched, and is preferably t-butyl.
• Z is selected from the group consisting of hydrogen, phenyl, indole, thienyl, benzothienyl, benzofuranyl, and benzimidazolyl.
• Z is phenyl, indolyl, thienyl, or benzothienyl.
• IA and IB are two preferred groupings of the subject compounds. These groups differ as for IA, R 2 is either hydrazino or hydrazono while in IB R 2 is hydrogen, amino, C 1-4 alkylcarbonylamino, cyano or halogen but Z is limited to indole, thiophene, benzothiophene, benzofuran, and benzimidazole.
• the pharmaceutically acceptable acid addition salts those salts in which the anion does not contribute significantly to toxicity or pharmacological activity of the organic cation, are preferred.
• the acid addition salts are obtained either by reaction of an organic base of structure I with an organic or inorganic acid, preferably by contact in solution, or by any of the standard methods detailed in the literature and available to any practitioner skilled in the art.
• useful organic acids are carboxylic acids such as maleic acid, acetic acid, tartaric acid, propionic acid, fumaric acid, isethionic acid, succinic acid, pamoic acid, cyclamic acid, pivalic acid, and the like; useful inorganic acids are hydrohalide acids such as HCl, HBr, HI; sulfuric acid; phosphoric acid; and the like.
• all the compounds of the present invention embrace all the optical isomer forms, that is, mixtures of enantiomers, e.g., racemic modifications as well as the individual enantiomers and diastereomers.
• the individual optical isomers of the propanolamine class of compounds of which the instant compounds are members have most generally been obtained by one of four basic methods. These are: (1) the fractional recrystallization of chiral acid salt derivatives; (2) derivatization with a chiral organic reagent, resolution and regeneration of the original compound in optically active form; (3) synthesis of the single optical isomer using chiral intermediates; and (4) column chromatography utilizing chiral stationary phases. The application of these various methods are well known to practitioners in the art.
• Biological testing of the subject compounds of Formula I in animals demonstrates that they possess potent vasodilating properties along with varying degrees of adrenergic beta-receptor blocking properties and intrinsic sympathomimetic activity.
• Preferred members have a particularly desirable combination in the foregoing actions, and ancillary pharmacological effects, or lack thereof, which particularly suits them for specific cardiovascular indications, e.g. use as antihypertensives.
• the utility of the compounds of Formula I can be demonstrated in various animal models including antagonism of isoproterenol in the anesthetized dog treated intravenously (adrenergic beta- receptor action), the spontaneous hypertensive and DOCA salt hypertensive rat (antihypertensive action), angiotensin-maintained ganglion-blocked rat model (vasodilator action) and in various other animal and laboratory models (cf: Deitchman, et al., Journal Pharmacological Methods, 3, 311-321 (1980)).
• therapeutic processes of this invention comprise systemic administration, by both oral and parenteral routes, of an effective, non-toxic amount of a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof.
• An effective amount is construed to mean a dose which exerts the desired pharmacological activity, such as those stated hereinabove, without undue toxid side effects when administered to a mammal in need of such treatment. Dosage will vary, according to the subject and route of administration selected, with an expected range of about 0.1 mcg to 100 mg/kg body weight for a compound of Formula I or a pharmaceutically acceptable acid addition salt thereof generally providing the desired therapeutic effect.
• the basic structure (I) for compounds of the present invention can be assembled by a convenient general process. This process involves the coupling of a X-substituted pyrimidine (IV) with a suitable W-substituted propanol or incipient propanol intermediate (III) followed by hydrolysis and/or aminolysis, if required, with the substituted amino component of the Formula I compound. ##STR4##
• D is hydrogen, or preferably phenyl
• G is the radical [-alk-Z]
• X is hydroxyl or halogen, preferably chloride
• W is halogen, preferably chloride, when X is hydroxyl and is hydroxyl when X is halogen.
• the hydroxyl-bearing reactant is initially converted to the oxide anion with a strong base prior to reaction with the halogen-bearing intermediate.
• This process employs methods known in the prior art for the preparation of 1-(substituted amino)-3-hetaryloxy)-2-propanols as disclosed in the patents and publications cited in "Background of the Invention" section of this disclosure.
• the process involves reaction of the appropriately substituted pyrimidine with either (A) a 3-(G-substituted oxazolidin-5-yl)methanol (or methyl halide) to give IIA, followed by hydrolysis; or (B) a G-substituted aminopropanediol (or halopropanol) of Formula IIB; or (C) glycidol to give IIC, followed by amination with H 2 NG; or (D) the cyclic ketal to give IID, followed by hydrolysis, activation of the terminal hydroxy, and aminolysis of H 2 NG.
• Method B is preferred in the above process.
• the hydrolysis steps in the above general process are usually accomplished with dilute mineral acid of from 0.1N to 1N concentration at temperatures of from about 20°-100° C.
• the amination reactions of the general process can be carried out simply by heating an amine of the Formula H 2 NG with an epoxy ether (IIC) or a propanediol (from IID) either neat or in the presence of a reaction inert organic solvent. No catalyst or condensation agent is required. Suitable reaction temperatures are from about 60°-200° C.
• routes A-D are shown below in greater detail.
• This scheme is carried out by reacting the chloropyrimidine (IV) with the potassium salt of 3-(1,1-dimethylethyl)-2-phenyl-5-oxazolidine-methanol (IIIA) followed by acidic hydrolysis of IIA to provide the corresponding structure I product.
• chloropropanediol is treated with an appropriate amine (V) in ethanol.
• Pathway D involves formation of the anion of solketal (IIID) followed by coupling with a chloropyrimidine (IV). Acid hydrolysis of the pyrmidinyloxy ketal (IID) provides the corresponding pyrimidinyloxypropanediol (VI). Following activation of the terminal hydroxy group, amination with V gives the structure I product.
• R 1 is hydrogen, C 1-6 alkyl, amino, C 1-4 alkylcarbonylamino, cyano or halogen
• R 2 is --NHNH 2 or ##STR13## with R a and R b being the same or different and representing C 1-3 alkyl or phenyl
• alk is C 1-6 alkylene, either straight chain or branched
• the four method variations shown as a-d represent optional synthetic pathways which may be selected for the initial step of the process.
• the process is completed either by introduction of the hydrazine group in Step 2, if the hydrazine product is desired, or with hydrazone formation (Step 3), if a hydrazone product is desired.
• the total process comprises:
• Step 2 If the desired end product is a hydrazone derivative, then the hydrazine derivative obtained in Step 2 is treated with an appropriate carbonyl compound VII ##STR26## with R a and R b the same as defined hereinabove, under acidic conditions to obtain the product of structure ##STR27##
• R 1 is hydrogen, C 1-6 alkyl, amino, C 1-4 alkylcarbonylamino, cyano, or halogen
• R 2 is hydrogen, amino, C 1-4 alkylcarbonylamino, halogen, or phenyl
• alk is C 1-6 alkylene, either straight chain or branched
• Z is selected from the group consisting of indole, thiophene, benzothiophene, benzofuran, and benzimidazole; the process comprises selection and use of one of the following variations (a-d).
• the IB synthetic process comprises:
• the compounds of the present invention can be formulated according to conventional pharmaceutical practice to provide pharmaceutical compositions of unit dosage form comprising, for example, tablets, capsules, powders, granules, emulsions, suspensions, and the like.
• the solid preparations contain the active ingredient in admixture with non-toxic pharmaceutical excipients such as inert diluents, for example, calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, maize, starch, or alginic acid; binding agents, for example, starch, gelatin or acacia; and lubricating agents, for example, magnesium stearate, stearic acid or talc.
• inert diluents for example, calcium carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate
• granulating and disintegrating agents for example, maize, starch, or alginic acid
• binding agents for example
• the tablets may be uncoated or they may be coated by known techniques so as to defy disintegration at absorption in the gastrointestinal tract and thereby provide a sustained action over a longer period.
• Liquid preparations suitable for parenteral administration include solutions, suspension, or emulsions of the compounds of Formula I.
• the aqueous suspensions of the pharmaceutical dosage forms of the compounds of Formula I contain the active ingredient in admixture with one or more non-toxic pharmaceutical excipients known to be suitable in manufacture of aqueous suspensions.
• Suitable excipients are, for example, suspending agents such as sodium carboxymethylcellulose, methylcellulose, hydroxypropyl methylcellulose, sodium alginate, polyvinylpyrrolidone, gum horrcanth and gum acacia.
• Suitable disbursing or wetting agents are naturally occuring phosphatides, for example, lecithin, polyoxyethylene stearate.
• Non-aqueous suspensions may be formulated by suspending the active ingredient in vegetable oil, for example, olive oil, sesame oil, or coconut oil, or in a mineral oil, for example, liquid parafin.
• the suspensions may contain a thickening agent such as beeswax, hard paraffin, or cetyl alcohol.
• Sweetening and flavoring agents generally used in pharmaceutical compositions may also be included such as saccharin, sodium cyclamate, sugar and caramel to provide a palatable oral preparation.
• the compositions may also contain other absorbing agent, stabilizing agents, wetting agents, and buffers.
• This indolyl amide was dissolved in 100 mL tetrahydrofuran and the resulting solution added dropwise to a stirred suspension comprised of 3 g lithium aluminum hydride in 50 mL of tetrahydrofuran under a nitrogen atmosphere. After being refluxed for 2 hr, the reaction mixture was cooled and decomposed with a small amount of water and dilute sodium hydroxide solution. The resulting mixture was filtered and the filtrate concentrated to a residual oil which was taken up in ethanol and treated with a slight excess of dimethyl sulfate. The resulting alcoholic solution was stirred at room temperature for 4 hr and then concentrated in vacuo to dryness giving as residue the trimethylamine quaternary salt.
• the crude quaternary salt product (3.0 g, 0.01 mole) was combined with NaOH (2.0 g pellets, 0.05 mole) and 2-nitropropane (15 mL) and the mixture was heated at reflux under a nitrogen atmosphere for 1 hr.
• the resultant dark thick mixture was cooled, diluted with water, acidified with acetic acid to a pH of approximately 6 and then extracted with ether.
• the ether extracts were combined, washed with water, dried (MgSO 4 ) and concentrated to a dark residue which was chromatographed on a silica column and diluted with methylene chloride.
• Additional intermediates of this class can either be obtained commercially, prepared by known procedures in the literature (e.g. 2-(3-indolyl)-1,1-dimethylethylamine is prepared by the method of Snyder, et al., J. Am. Chem. Soc., 69, 3140 (1947) from 3-indolyl-methyldimethylamine (gramine) and 2-nitropropane followed by reduction of resulting 2-(3-indolyl)-1,1-dimethylnitroethane); or by modification of the foregoing synthetic examples.
• intermediates wherein Z is benzofuran or positional isomers of thiophene and benzothiophene can be prepared.
• 3-(1,1-Dimethylethyl)-2-phenyl-5-oxazolidinemethanol (8.2 g, 0.035 mole, prepared according to the method disclosed in U.S. Pat. No. 3,998,835 issued Dec. 21, 1976 and assigned to Sandoz, Ltd.) was dissolved in tetrahydrofuran (60 mL) and treated dropwise, under nitrogen, with 24% potassium hydride in mineral oil (5.4 g, 0.032 mole). After stirring at 25° for 10 min, the mixture was heated at 45° for 1 hr.
• 2,4-Diamino-6-chloropyrimidine (4.3 g, 0.03 mole) was added and the mixture heated in a 100 mL stainless steel Parr bomb at 100°-105° for 18 hrs. After cooling, a yellow insoluable gum was collected. The filtrate was concentrated to an oil, from which three crops of solid (m.p. 92°-105°) were isolated by trituration with CCl 4 and ether.
• the oxazolidine intermediate (IIA, prepared in Example 5) was hydrolyzed by stirring with 40 ml. of 1N HCl at 45°-50° for 1 hr. After cooling, the solution was washed with ether, made basic with 15% NaOH, and extracted with ethyl acetate. The extracts were dried (K 2 CO 3 ), concentrated in vacuo and the residue dissolved in acetone. The acetone solution was acidified with ethanolic HCl, concentrated, and the residue recrystallized from methanol-isopropyl ether to give 1.4 g (32%), m.p. 221°-223° (dec).
• the reaction mixture was stirred at 25° for 6 hrs, allowed to stand overnight, and evaporated to dryness.
• the residue was slurried in ethyl acetate and water, the organic layers dried (MgSO 4 ) and concentrated to a gummy residue.
• the gum was triturated in warm dilute hydrochloric acid, filtered, made basic with dilute sodium hydroxide solution and extracted with ethyl acetate. After drying (MgSO 4 ), the ethyl acetate extract was concentrated in vacuo, the residue dissolved in isopropyl alcohol and acidified with ethanolic HCl.
• the precipitated hydrochloride (7.0 g) was recrystallized twice from methanol-ethyl acetate to afford 4.9 g (27%) product, m.p. 192°-195° (dec).
• IR (KBr): 795, 1010, 1140, 1250, 1305, 1340, 1445, 1570, 1600, 1650, 2980, 3200, and 3360 cm -1 .
• Example 14 The hydrazino pyrimidine compound prepared in Example 14 (1.6 g, 3.4 mmole) was suspended in isopropyl alcohol (15 mL), acidified with ethanolic HCl, and warmed while adding acetone (3 mL). Crystalline dihydrochloride separated from the hot solution. The mixture was filtered to provide 1.9 g (94%) of analytically pure product, m.p. 197°-199° (dec).
• IR (KBr): 760, 1110, 1160, 1425, 1478, 1610, 1640, 2800, and 2980 cm -1 .
• Additional product I compounds can be prepared using methods contained in the foregoing examples. A tabulation of some selected additional compounds of Formula I appears in Table 1.
• the angiotensin-maintained ganglion-blocked rat model is utilized as a screening test for estimation of the vasodilator component of activity. Percentage changes in blood pressure in anesthetized rats 30 minutes after intravenous dosing are determined. The intravenous dosing is done with test compounds at 3 mg/kg. Borderline activity is defined as approximately a 10% decrease in blood pressure measured 30 minutes after dosing. "Active" and “inactive" designations are increases greater and less than that.
• Diastolic blood pressure and heart rate responses to a fixed challenge dose of isoproterenol are obtained before and 15 minutes after graded doses to test compound administered intravenously over a 3 minute interval to anesthetized dogs.
• a branch of a femoral artery and vein are cannulated to record blood pressure and to administer the drugs which are dissolved in saline.
• the vagi were sectioned bilaterally in the mid-cervical region of the neck and the dogs are ventilated mechanically (Harvard respiratory) with room air at a rate of 20/minute and a stroke volume of 20mL/kg.
• Heart rate is monitored with a cardiotachometer triggered by the pressure pulse. All measurements are recorded on a Beckman R-612 recorder.
• the drug effect is expressed in terms of a cumulative dose (microgram/kg) causing 50% inhibition of isoproterenol response.
• Rats Male Wistar are anesthetized with a combination of urethane and chloralase intraperitoneally. Following induction of anesthesia, chlorisondamine is injected into the peritoneal cavity to produce ganglion blockage. A femoral artery was cannulated to monitor blood pressure and heart rate and two femoral veins were cannulated to administer compounds. The trachea ws intubated and rats were allowed to breath spontaneously. Animals were challenged before and 15 minutes after intravenous administration of test compound with graded doses of isoproterenol and the changes in heart rate recorded.

Landscapes

• Chemical & Material Sciences (AREA)
• Organic Chemistry (AREA)
• Health & Medical Sciences (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Life Sciences & Earth Sciences (AREA)
• Cardiology (AREA)
• Heart & Thoracic Surgery (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Medicinal Chemistry (AREA)
• Engineering & Computer Science (AREA)
• Pharmacology & Pharmacy (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Animal Behavior & Ethology (AREA)
• General Health & Medical Sciences (AREA)
• Public Health (AREA)
• Veterinary Medicine (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Plural Heterocyclic Compounds (AREA)
• Heterocyclic Compounds Containing Sulfur Atoms (AREA)
• Indole Compounds (AREA)

Priority Applications (27)

Applications Claiming Priority (1)

Publications (1)

Family

ID=23958998

Family Applications (1)

Country Status (25)

Cited By (9)

Families Citing this family (9)

Citations (6)

Family Cites Families (10)

• 1983
  • 1983-05-09 US US06/493,124 patent/US4517188A/en not_active Expired - Fee Related
• 1984
  • 1984-05-04 KR KR1019840002428A patent/KR900005015B1/ko not_active IP Right Cessation
  • 1984-05-04 ZA ZA843378A patent/ZA843378B/xx unknown
  • 1984-05-04 FR FR8406989A patent/FR2545825B1/fr not_active Expired
  • 1984-05-07 NL NL8401450A patent/NL8401450A/nl not_active Application Discontinuation
  • 1984-05-08 FI FI841841A patent/FI80268C/fi not_active IP Right Cessation
  • 1984-05-08 IT IT20841/84A patent/IT1175492B/it active
  • 1984-05-08 SE SE8402476A patent/SE466309B/sv not_active IP Right Cessation
  • 1984-05-08 DK DK227884A patent/DK166583C/da active
  • 1984-05-08 CA CA000453766A patent/CA1279064C/en not_active Expired - Fee Related
  • 1984-05-08 GR GR74645A patent/GR81557B/el unknown
  • 1984-05-08 ES ES532282A patent/ES8604529A1/es not_active Expired
  • 1984-05-08 GB GB08411636A patent/GB2139623B/en not_active Expired
  • 1984-05-08 DE DE19843416976 patent/DE3416976A1/de not_active Ceased
  • 1984-05-08 IE IE1137/84A patent/IE57410B1/en not_active IP Right Cessation
  • 1984-05-08 BE BE0/212896A patent/BE899608A/fr not_active IP Right Cessation
  • 1984-05-08 AU AU27792/84A patent/AU576761B2/en not_active Ceased
  • 1984-05-08 CH CH2253/84A patent/CH659247A5/de not_active IP Right Cessation
  • 1984-05-09 LU LU85354A patent/LU85354A1/fr unknown
  • 1984-05-09 JP JP59091166A patent/JPS59206364A/ja active Pending
  • 1984-05-09 PT PT78570A patent/PT78570A/pt not_active IP Right Cessation
  • 1984-05-09 AT AT1522/84A patent/AT392966B/de not_active IP Right Cessation
• 1985
  • 1985-07-15 ES ES545198A patent/ES8704154A1/es not_active Expired
• 1986
  • 1986-02-13 ES ES551966A patent/ES8702372A1/es not_active Expired
• 1990
  • 1990-01-19 SG SG48/90A patent/SG4890G/en unknown
  • 1990-03-08 HK HK175/90A patent/HK17590A/xx unknown
  • 1990-11-16 CY CY1522A patent/CY1522A/xx unknown

Patent Citations (6)

Non-Patent Citations (1)

Also Published As

Similar Documents

Legal Events